Industry
Biotechnology
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Loading...
Open
1.25
Mkt cap
26M
Volume
92K
High
1.29
P/E Ratio
-1.05
52-wk high
4.59
Low
1.21
Div yield
N/A
52-wk low
1.15
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.